Should SBRT be THE preferred treatment for intermediate-risk prostate cancer?

Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …

Focal HIFU in treatment of (largely) intermediate-risk prostate cancer

In addition to the French data previously referred to on this site, data from another, much larger cohort of men treated with focal, high-intensity focused ultrasound (focal HIFU) are also to be presented at the upcoming annual meeting of the American Urological Association. … READ MORE …

Toxicity higher with hypofractionation in Dutch radiotherapy trial using 3D-CRT

A Dutch research group has published the toxicity outcomes of a randomized clinical trial (HYPRO) designed to test whether a hypofractionated external beam (EBRT) regimen compared to conventional fractionation. They will report on the oncological outcomes at a later date. … READ MORE …

Neoadjuvant chemotherapy prior to surgery in higher-risk patients

A combined Russian and German research team has provided some interesting preliminary information on the use of neoadjuvant, low-dose docetaxel-based chemotherapy in treatment of intermediate- and high-risk patients prior to radical prostatectomy. … READ MORE …

The potential of low-dose enzalutamide in intermediate-risk prostate cancer

A case study report in the journal Research and Reports in Urology (which is not exactly a widely read publication) addresses the treatment of an elderly man with low-risk prostate cancer with low-dose enzalutamide as a form of first-line therapy. … READ MORE …

SBRT in men with intermediate-risk, localized prostate cancer

Data reported by Meier et al. and presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) provide some early guidance on the efficacy and safety of sterotactic body radiation therapy (SBRT) in treatment of men with intermediate-risk, localized prostate cancer. … READ MORE …